Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA:603567)

China · Delayed Price · Currency is CNY

5.38

-0.16 (-2.89%)

Sep 10, 2026, 11:29 AM CST

SHA:603567 Financials Overview

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	379.45	797.34	2,704	3,138	4,214	4,127
Revenue Growth	-78.40%	-70.51%	-13.84%	-25.53%	2.12%	21.24%
Gross Profit	-707.04	-393.5	1,370	1,292	675.25	1,298
Operating Income	-1,237	-1,123	602.9	185.52	-216.71	270.38
Net Income	-1,559	-1,367	438.22	472.74	185.44	332.1
Earnings Per Share	-1.66	-1.45	0.47	0.50	0.20	0.38
EPS Growth	-	-	-7.30%	155.28%	-48.71%	-25.24%

Revenue by Segment

Fiscal Year	FY 2025
Period Ending	Dec '25 Dec 31, 2025
Industry	446.51
Commercial and Medicinal Sales	321.96
Total	768.47

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	64.97	84.09	1,069	1,469	1,061	1,565
Total Debt	3,144	3,118	3,294	3,151	2,926	2,945
Net Cash (Debt)	-3,079	-3,034	-2,225	-1,682	-1,865	-1,380
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-3.28	-3.23	-2.37	-1.79	-1.98	-1.60

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	487.29	322.1	164.31	-478.24	-326.79	-433.94
Capital Expenditures	-42.81	-68.52	-189.15	-95.14	-404.27	-448.63
Free Cash Flow	444.48	253.57	-24.84	-573.38	-731.07	-882.57
Free Cash Flow Growth	345.83%	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-186.33%	-49.35%	50.67%	41.18%	16.02%	31.45%
Operating Margin	-325.96%	-140.88%	22.30%	5.91%	-5.14%	6.55%
Pretax Margin	-484.91%	-204.10%	19.36%	15.24%	7.08%	11.02%
Profit Margin	-410.91%	-171.39%	16.21%	15.06%	4.40%	8.05%
FCF Margin	117.14%	31.80%	-0.92%	-18.27%	-17.35%	-21.39%

Dividends

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Dividend Per Share	0.150	0.200	0.028	0.106
Dividend Per Share Growth	-25.00%	614.29%	-73.58%	-
Dividend Yield	1.31%	1.70%	0.23%	0.72%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 10, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
PE Ratio	-	-	24.87	24.16	64.65	43.40
Forward PE	-	18.18	18.18	18.18	18.18	22.34
P/FCF Ratio	11.71	33.08	-	-	-	-
PS Ratio	13.71	10.52	4.03	3.64	2.85	3.49